Vaxil Bio Ltd V.VXL

Alternate Symbol(s): VXLLF

Healthcare Biotechnology

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.

TSXV:VXL - Post by User

Vaxil Bio Ltd

Bullboard Posts

Post by Covid19on Mar 21, 2020 10:01pm

267 Views

Post# 30834403

Vaxil Bio's Coronavirus Vaccine

Vaxil’s lead product ImMucin™ (which the Covid-19 vaccine is based on protein based peptides) successfully completed a Phase 1/2 clinical trial and received orphan drug status by the FDA and EMA. Vaxil’s patent portfolio is segmented into 3 families, consisting of 6 issued and 10 pending patents. The video below is an older one, but still substancial in showcases the companies potential.